In mid-February 2015 we learned that a new treatment for malignant mesothelioma will be available in the US.
From this article, “FDA grants orphan drug designation to VS-5584 for mesothelioma”, we get the following information:
The FDA granted orphan drug designation to VS-5584 for the treatment of mesothelioma, according to a press release from the drug’s manufacturer….
“This is an important regulatory milestone for Verastem and, together with our European orphan medicinal product designation, will facilitate our global development of VS-5584 to help improve the available treatment options for patients suffering from this highly aggressive cancer,” Robert Forrester, president and CEO of Verastem, said in a press release. “We look forward to taking full advantage of the opportunities that orphan designation allows in order to bring this potential new treatment option to patients as rapidly as possible.”
Verastem is currently conducting a phase 1 study to evaluate the combination of VS-5584 and VS-6063 (defactinib) in patients with relapsed or progressive malignant pleural mesothelioma. Preclinical data demonstrated synergistic activity of VS-5584 and defactinib in mesothelioma models in vitro and in vivo.
We have reported on Verastem’s earlier mesothelioma treatment, VS-6063, over the past couple of years in these articles:
- Verastem Says Its VS-6063 Mesothelioma Treatment Study Is On-Track And Showing Some Promising Results (1/9/15)
- Investigational Mesothelioma Treatment VS-6063 From Verastem Granted Orphan-Drug Status In European Union (7/5/13)
- FDA Allows Experimental Cancer Drug VS-6063 To Move Forward And Possibly Be New Mesothelioma Treatment In U.S. (8/9/13)
- Mesothelioma Medical Update: February 2013: Two New Experimental Mesothelioma Treatment Drugs (2/28/13)
Of course we will continue to monitor developments announced by Veratstem and other medical companies working on new treatments for mesothelioma.
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.